Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced ...

Rebranding efforts include a new logo, overall brand presence, and corporate design.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Knight Therapeutics Inc. GUD-T has signed a deal to buy the assets of Paladin Pharma Inc. as the Canadian drug company looks to build out its domestic business after a strategic push into South ...

Warren, Wyden, and Sanders wrote to Kennedy that “the dinners may have served as an opportunity for Big Pharma to gain insider access to both you and President Trump” and asked the HHS chief to reveal ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Try Now>> See the top stocks recommended by analysts >> Read More on URGN: UroGen Pharma NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

MUMBAI, India and WALTHAM, Mass., March 9, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE ...

March 10 (Reuters) - India's Sun Pharmaceutical Industries (SUN.NS), opens new tab said on Monday it will acquire Checkpoint Therapeutics (CKPT.O), opens new tab, a U.S.-based immunotherapy and ...

SAN DIEGO (FOX 5/KUSI) — The former vice president of Acadia Pharmaceuticals Inc., headquartered in Sorrento Valley, pleaded guilty Friday to insider trading. George Demos, 64, of San Diego ...

HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its ...

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) reported a significant increase in cash equivalents and short-term investments, ending 2024 with $238 million compared to $170 million in 2023.